| SFDA Approved Use |
Efavirenz is indicated in antiviral combination treatment of human immunodeficiency virus 1
(HIV 1) infected adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg. Efavirenz has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm 3, or after failure of protease inhibitor (PI) containing regimens. Although cross resistance of Efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI based combination therapy after failure of regimens containing Efavirenz. For a summary of clinical and pharmacodynamic information. |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 25 Jun 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Government websites use the protocol. HTTPS for encryption and security.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.